Marshall Wace, LLP Prothena Corp Public LTD CO Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $524,537 - $854,194	10,869 New	10,869 $742,000
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $1.78 Million - $4.28 Million	-70,584 Reduced 39.57%	107,803 $6.54 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $3.82 Million - $6.71 Million	167,861 Added 1594.73%	178,387 $4.84 Million
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $6.18 Million - $10 Million	-204,165 Reduced 95.1%	10,526 $385,000
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $6.14 Million - $10.7 Million	145,799 Added 211.63%	214,691 $10.6 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $3.32 Million - $5.43 Million	68,892 New	68,892 $4.91 Million
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $509,451 - $1.36 Million	-23,553 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $434,720 - $1.12 Million	-39,520 Reduced 62.66%	23,553 $591,000
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $638,298 - $879,237	63,073 New	63,073 $758,000
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $1.2 Million - $1.81 Million	-173,557 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$8.85 - $12.49 $1.54 Million - $2.17 Million	173,557 New	173,557 $1.83 Million
Q4 2018 Feb 14, 2019	SELL	$8.73 - $13.74 $127,746 - $201,057	-14,633 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$12.7 - $15.79 $185,839 - $231,055	14,633 New	14,633 $191,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.